Slide 1: Annual Meeting of Shareholders
Annual Meeting of Shareholders 25 August 2016
Slide 2: Board of Directors
BOARD OF DIRECTORS Refreshed Board With A Range Of Complementary Skills and Expertise Chris Swann Retiring Chairman GOVERNANCE Board of Directors Chris Gallaher Independent Director Incoming Chairman Experience in governance, finance, cancer research, biotechnology and life sciences, investment and
Slide 3: Retiring Chairman
RETIRING CHAIRMAN Chris Swann Appointed 2005 Company Highlights 2005 to 2016: • Evolution of Pacific Edge from a research organisation to a commercial entity • Development of commercial strategy in New Zealand and Australia • Expanded footprint in the USA • Extension of strategy to include “One-Stop
Slide 4: Incoming Chairman
INCOMING CHAIRMAN Chris Gallaher Appointed 1 July 2016 Experienced business leader with a background in financial and general management International experience in both public and private companies Recently retired as Chief Financial Officer at Fulton Hogan Ltd Prior to this, held CFO and CEO roles
Slide 5: Meeting Agenda
MEETING AGENDA • Presentations: • Address from the Retiring Chair and the Incoming Chair • Address from the Chief Executive Officer, David Darling • Shareholder Discussion • Resolutions as per Notice of Meeting • Re-election of David Band as a Director • Election of David Levison as a Director • Ele
Slide 6: Chief Executive Officer
CHIEF EXECUTIVE OFFICER David Darling Pacific Edge 2016 Annual Meeting 6
Slide 7: Our Purpose and Strategy
OUR PURPOSE AND STRATEGY Delivering Innovative Solutions for the Early Detection and Management of Cancer OUR OFFER Focus on bladder cancer; building a suite of Cxbladder tests OUR MARKETS Targeting large scalable markets Primary market is the USA. Cxbladder tests are also sold commercially in Austr
Slide 8: One Stop Shop of Cxbladder Products
ONE STOP SHOP OF CXBLADDER PRODUCTS Non-invasive, Accurate, Fast, Easy To Use And Cost Effective PRIMARY HEALTHCARE (General Practitioner) 80% 20% CXBLADDER TRIAGE For use by physicians and urologists Triage out patients who present with haematuria and have a low probability 1 MILLION PATIENTS WITH
Slide 9: Positive Progress on Our Commercial Pathway
POSITIVE PROGRESS ON OUR COMMERCIAL PATHWAY FY16 was another year of positive progress and growth for Pacific Edge as we continued to gain market traction with our Cxbladder products Pacific Edge 2016 Annual Meeting 9
Slide 10: FY16 Highlights
FY16 HIGHLIGHTS Another Year of Commercial Progress and Growth In Targeted Markets Uplift in Commercial Milestone Achievements Good Commercial Launch of Third Revenue in the USA Progress in Other Product, Cxbladder Markets Monitor Growing customer Expanded USA sales New commercial Launched to plan i
Slide 11: FY16 Revenue
FY16 REVENUE Uplift in Product Sales In the past two years, operating revenue has grown from $150,000 to $4.98 million OPERATING REVENUE 162% increase Continuing growth in product sales, in operating particularly in North America revenue compared to the previous year Third year of funding from a $4.
Slide 12: FY16 Financial Snapshot
FY16 FINANCIAL SNAPSHOT Continuing Investment into Four Strategic Areas PEOPLE FY16 FY15 • Expansion of the USA sales team to 18 executives $NZ’000 $NZ’000 • Increased the commercial, marketing and Total Revenue and Income 7,193 4,132 product development teams in New Zealand Total Expenses 22,870 16
Slide 13: Good Progress Against FY16 Goals: Infrastructure and Customers
GOOD PROGRESS AGAINST FY16 GOALS Build Infrastructure; Capture Transformational Customers Capture Transformational Customers Build Infrastructure for Growth ACHIEVED: Completed the Federal Supply ACHIEVED: Expand to 18 sales executives Schedule process to gain access to the covering 19 targeted majo
Slide 14: Good Progress Against FY16 Goals: Awareness and International
GOOD PROGRESS AGAINST FY16 GOALS Awareness and Adoption; International Presence Grow Our International Presence Enhance Awareness and Foster Strong Adoption ACHIEVED: Established commercial infrastructure to enable evaluation and ONGOING: Continue to roll out User testing of the market Programmes to
Slide 15: Good Progress Against FY16 Goals: Product Launches
GOOD PROGRESS AGAINST FY16 GOALS One Stop Shop of Cxbladder Products; Launch New Products into Market Cxbladder Triage To be used by clinicians and physicians responsible for NZ Launch Dec 14 the primary detection of bladder cancer as a frontline USA Rollout 2015 tool in the early evaluation of haem
Slide 16: Good Progress Against FY16 Goals: Intellectual Property
GOOD PROGRESS AGAINST FY16 GOALS Intellectual Property; Engaging with the People Who Matter ONGOING: Protect Pacific Edge’s Engage with the People Who Matter intellectual property, over a range of diagnostic technologies, in markets ACHIEVED: Launched online patient around the world community for bl
Slide 17: Our Priorities for FY17 and Progress to Date
OUR PRIORITIES FOR FY17 AND PROGRESS TO DATE Pacific Edge 2016 Annual Meeting 17
Slide 18: Markets: USA
MARKETS Primary Focus On USA Healthcare Market UNITED STATES: PROGRESS TO DATE Remains the primary focus for growth Over 10,000 urologists and millions of potential • Sales team fully operational clinical opportunities for use of Cxbladder products • Moving at pace Growing knowledge base and underst
Slide 19: Markets: Other Markets
MARKETS Other Markets AUSTRALIA: PROGRESS TO DATE Work with Tolmar Australia to build awareness AUSTRALIA: and increase sales of Cxbladder tests in • Building awareness with three products Australia now available SOUTH EAST ASIA: • Tolmar Australia leveraging their Establish a base in Singapore for
Slide 20: Products
PRODUCTS Rollout Cxbladder Monitor; Launch Cxbladder Predict Rollout of Cxbladder Monitor into the United PROGRESS TO DATE States and Australia Launch Cxbladder Predict in New Zealand CXBLADDER MONITOR INTO THE USA • On track with launch into the USA, currently launching to targeted urologists and o
Slide 21: Customers
CUSTOMERS USA sales team continuing to target individual PROGRESS TO DATE urologists and large urology practices VETERANS ADMINISTRATION: Initial large VA sites have been targeted, underway Work with hospitals to gain acceptance of with marketing Cxbladder into their care pathways Agreed a list pric
Slide 22: Sales Channels
SALES CHANNELS Build Awareness, Encourage Adoption, Transition to Commercial Customer Continue to initiate new User Programmes and PROGRESS TO DATE transition early adopters into commercial customers USER PROGRAMMES: Identify and investigate new sales channels Now starting to see traction as User Pr
Slide 23: Strategic Opportunities for Growth
STRATEGIC OPPORTUNITIES FOR GROWTH Targeting High Growth Over The Medium Term by Creating More Products and Building Sales in an Increasing Number of Markets • Development of suite of Cxbladder products More Products • IP over other cancer expressions with opportunity to develop specific diagnostic
Slide 24: Our Future
OUR FUTURE Pacific Edge 2016 Annual Meeting 24
Slide 25: Shareholder Discussion
SHAREHOLDER DISCUSSION Pacific Edge 2016 Annual Meeting 25
Slide 26: Resolution: Re-election of David Band
RESOLUTION: Re-election of David Band That David Band, who retires by rotation and is eligible for re-election, be re-elected as a Director of the Company Pacific Edge 2016 Annual Meeting 26
Slide 27: Resolution: Election of David Levison
RESOLUTION: Election of David Levison That David Levison, who was appointed as a Director by the Board during the year and retires and puts himself forward for election, be elected as a Director of the Company Pacific Edge 2016 Annual Meeting 27
Slide 28: Resolution: Election of Chris Gallaher
RESOLUTION: Election of Chris Gallaher That Chris Gallaher, who was appointed as a Director by the Board during the year, and retires and puts himself forward for election, be elected as a Director of the Company Pacific Edge 2016 Annual Meeting 28
Slide 29: Resolution: Auditor's Remuneration
RESOLUTION: Auditor’s Remuneration That the Directors of the Company be authorised to fix the auditor's remuneration for the ensuing year Pacific Edge 2016 Annual Meeting 29
Slide 30: Voting
VOTING Voting instructions for those voting online are available at: http://www.linkissuers.co.nz/VirtualAnnualMeeting/OnlinePortalGuide.pdf Pacific Edge 2016 Annual Meeting 30
Slide 31: Proxies
PROXIES We have received the following valid votes and proxies: PROXIES AND POSTAL VOTES FOR AGAINST OPEN VALID % OF TOTAL VOTES/PROXIES ISSUED RECEIVED CAPITAL Re-election of David 118,918,426 22,568,365 1,914,472 143,401,263 37.57% Band (Resolution 1) 82.93% 15.74% 1.34% Election of David 118,984,
Slide 32: Other Business
OTHER BUSINESS Pacific Edge 2016 Annual Meeting 32
Slide 33: Close of the Meeting
CLOSE OF THE MEETING Presentations are available at www.pacificedgedx.com Pacific Edge 2016 Annual Meeting 33
Slide 34: Contact details
www.pacificedge.co.nz www.cxbladder.com www.pacificedgedx.com David Darling Chief Executive Officer Pacific Edge Limited Tel: +64 3 479 5802 Mobile: +64 21 797981 Email: david.darling@pelnz.com Pacific Edge 2016 Annual Meeting 34
Slide 35: Disclaimer
DISCLAIMER Information The information in this presentation is an overview and does not contain all information necessary to make an investment decision. It is intended to constitute a summary of certain information relating to the performance of Pacific Edge Limited . The information in this presen